Contract with Roche to Profile Autoantibodies

RNS Number : 1388O

Oncimmune Holdings PLC

28 May 2020

 

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

28 May 2020

Oncimmune Holdings plc

("Oncimmune" or the "Company")

Cornerstone Contract Signed with Roche to Profile Autoantibodies in Patients undergoing Immunotherapy Trials

Oncimmune extends its collaboration with Roche with substantial contract to be completed by November 2020

Strengthened relationship further demonstrates value of the Oncimmune Germany acquisition

Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics group, today announces that it has signed a further contract with Roche to profile autoantibodies in patient samples collected during cancer immunotherapy trials.

Following closely on the completion of a successful foothill project with Roche, which was undertaken over the last two months, this new contract provides Oncimmune with the opportunity to further contribute to the understanding of individual patient responses to immunotherapy through immune profiling.

The project will explore the baseline and on-treatment autoantibody profiles as biomarkers in patients that received cancer immunotherapy, using Oncimmune's proprietary SeroTag ^® biomarker discovery platform.

This contract, which has a substantial upfront element, will commence immediately, with initial results scheduled to be provided to Roche within three months, and project completion by November 2020.

This milestone contract evidences Oncimmune's broadening commercial footprint to not only deliver diagnostic tests, through EarlyCDT Lung and Liver, but also to partner with large pharmaceutical and biotechnology companies by profiling autoantibodies and developing commercial companion diagnostic tests through the service side of the business.

Dr Adam M Hill, CEO of Oncimmune said: "This significant contract with Roche not only builds upon the excellent collaborative work between the Oncimmune and Roche teams in recent months, but it strikes to the heart of understanding as to why cancer patients have differing responses to the same immunotherapy.

"Since acquiring Oncimmune Germany last year, we have grown the pipeline of potential commercial projects with major pharmaceutical and biotechnology companies, and this contract, the largest we have signed to date, provides further evidence of our ability to convert pipeline opportunities into contracted revenues.

"I look forward to announcing future projects with our partners over the coming weeks, and further unlocking the potential of our autoantibody platform to improve patient outcomes."

For further information:

Oncimmune Holdings plc

Adam Hill, Chief Executive Officer

Matthew Hall, Chief Financial Officer

[e-mail]

Zeus Capital Limited (Nominated Adviser and Joint Broker)

Andrew Jones, Daniel Harris, Victoria Ayton

[phone]

finnCap (Joint Broker)

Geoff Nash, Matthew Radley, Tim Redfern

[phone]

Bryan, Garnier & Co Limited (Joint Broker)

Phil Walker, Dominic Wilson

[phone]

Media enquiries:

FTI Consulting

Ben Atwell, Michael Trace, Alex Davis

[e-mail]

[phone]

About Oncimmune

Beating cancer, one test at a time

The battle against cancer hinges on early detection and then the delivery of effective treatment. Oncimmune is working to revolutionise both the detection of cancer and its treatment by harnessing the sophisticated disease detecting capabilities of the immune system to find cancer in its early stages. Our range of diagnostic tests assist clinicians to identify the presence of cancer four years or more before standard clinical diagnosis, whilst our technology platform and sample biobanks are helping healthcare companies to develop new cancer treatments.

Oncimmune was founded in 2002 and launched its platform technology in 2009, followed by its first commercial tests, EarlyCDT Lung and EarlyCDT Liver. To date, over 158,000 tests have been performed for patients worldwide. EarlyCDT Lung was also used in what is believed to be the largest randomised controlled trial for the early detection of lung cancer using biomarkers, the successful National Health Service (NHS) ECLS trial of 12,209 high-risk smokers in Scotland which demonstrated EarlyCDT Lung reduced the incidence of patients with late-stage lung cancer or unclassified presentation at diagnosis, compared to standard clinical practice.

Oncimmune, headquartered at its laboratory facility in Nottingham, UK, has a discovery research centre in Dortmund, Germany and in London, UK and a partner representative office in Shanghai, China. Oncimmune joined the Alternative Investment Market (AIM) of the London Stock Exchange in May 2016 under the ticker ONC.L.

What is SeroTag ^® ?

SeroTag ^® is Oncimmune's proprietary biomarker discovery engine, which is used to discover and validate novel biomarkers that can help stratify different cancer indications and autoimmune diseases.

For more information, visit  www.oncimmune.com

 

END

 

 

CNTDDLFLBELZBBX